Astrazeneca (AZN) Current Deferred Revenue (2018 - 2020)

Astrazeneca (AZN) has reported Current Deferred Revenue for 3 consecutive years, with $12.0 million the latest figure, recorded in Q4 2020.

• In Q4 2020, Current Deferred Revenue fell 57.14% year-over-year to $12.0 million; the TTM figure through Dec 2020 stood at $12.0 million (down 57.14% YoY), while the FY2020 annual figure was $12.0 million, down 57.14% from the prior year.
• Current Deferred Revenue came in at $12.0 million for Q4 2020 at Astrazeneca, down from $28.0 million in the prior quarter.
• The five-year high for Current Deferred Revenue was $92.0 million in Q4 2018, with the low at $12.0 million in Q4 2020.
• Average Current Deferred Revenue over 3 years is $44.0 million, with a median of $28.0 million recorded in 2019.
• Across the five-year window, Current Deferred Revenue tumbled 69.57% in 2019 and sank 57.14% in 2020, its largest moves.
• Year by year, Current Deferred Revenue stood at $92.0 million in 2018, then sank by 69.57% to $28.0 million in 2019, then tumbled by 57.14% to $12.0 million in 2020.
• According to Business Quant data, Current Deferred Revenue over the past three periods registered $12.0 million, $28.0 million, and $92.0 million for Q4 2020, Q4 2019, and Q4 2018 respectively.